Injection of natural killer cells for treating gliomas
Official title: Efficacy of the Intrathecal Injection of Active Allogeneic Natural Killer Cells in Patients With High-grade Gliomas; A Multi-center Phase II Clinical Trial
Run by Kian Immune Cell Company · NCT06687681 · Data updated 2026-11-12
This study is testing whether a new treatment using natural killer cells can help young patients with high-grade gliomas, like glioblastoma, fight their cancer better.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 3 Years to 70 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Kian Immune Cell Company Industry-sponsored |
| Drugs / interventions | Immunotherapy, radiation |
| Locations | 1 site (Tehran) |
| Status | Recruiting |
| Started | November 25, 2024 |
| Main results expected | November 25, 2025 |
| Study ends | November 25, 2027 |
| Registry record updated | April 9, 2025 |
| Trial ID | NCT06687681 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include newly diagnosed patients aged 3 to 60 with grade 3 or 4 gliomas, such as glioblastoma or other specified high-grade tumors.
✕Probably not a fit
Patients with evidence of radio necrosis, other malignancies, or significant uncontrolled chronic diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of active allogeneic natural killer (NK) cells as a treatment for patients diagnosed with high-grade gliomas, including glioblastoma. The study focuses on patients aged 3 to 60 years who meet specific health criteria and have not previously undergone treatment for their tumors. Participants will receive NK cell therapy, which aims to enhance the immune response against cancer cells. The trial seeks to evaluate the safety and efficacy of this immunotherapy approach in improving patient outcomes.
Why it matters
Potential benefit: If successful, this treatment could provide a novel immunotherapy option that may improve survival rates for patients with high-grade gliomas.
How similar studies have gone: Other studies have shown promise in using immunotherapy approaches like NK cell therapy for various cancers, indicating potential success for this novel application in gliomas.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: New diagnosed patients with grade 3 or 4 brain tumor, based on WHO classification, which are included in the one of the following conditions: • Astrocytoma, IDHmutant • Oligodendroglioma, IDH-mutant • Glioblastoma, IDH-wild type • Diffuse midline glioma • Diffuse hemispheric glioma • Diffuse pediatric-type high-grade glioma, IDH-wild type Age range of 3 to 60 years old both sex Lansky/Karnofsky performance score above 60 Obtained informed consent of patients or parents or legal attendance in cases of pediatrics Hemoglobin above 10 gr/dL of blood Absolute granulocyte count (AGC) above 500 per microliter of blood Platelet count above 50000 per microliter of blood INR below 2 and PTT less than 1.5 times of maximum normal value Plasma bilirubin level less than 1.5 times of maximum normal value Plasma hepatic transaminases (ALT and AST) level less than 3 times of maximum normal value Plasma creatinine level less than 1.5 times of maximum normal value - Exclusion Criteria: Evidence of radio necrosis in MRI or MRS Intolerance of new treatment due to emergency condition History of other malignancies History of any immunodeficiency diseases or any immune compromising conditions Rupture of cerebral shunt or unable to perform a lumbar puncture Pregnancy History of uncontrolled chronic diseases such as: Diabetes, CHF, liver cirrhosis, CKD, etc \-
Where it's running
-
Rasoul Akram hospital
Tehran, Iran Recruiting
Study contacts
- Study coordinator: Marzieh Ebrahimi, PhD
- Email: mebrahimi@royan-rc.ac.ir
- Phone: +98 21 235 62516
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Taste of hope: testing NRG-103 safety and dosing for adults with high-grade glioma
This early-phase trial tests whether NRG-103 is safe and tolerable in adults with recurrent or progressive high-grade glioma and looks for early signs it might help.
-
Midline glioma MRI AI model: preoperative molecular subtyping and prognosis
This study tests an MRI-based AI model to predict key molecular subtypes and prognosis for patients with midline gliomas before surgery.
-
PET-guided surgery for high-grade glioma
This project will try using 18F-DOPA PET to guide surgeons to remove tumor beyond MRI-visible areas in adults with high-grade glioma to see if it delays progression and extends survival.
-
Fluorescence-enhanced stereotactic biopsy needle for tumor and vessel detection
This project will test a biopsy needle fitted with 5-ALA fluorescence, Raman spectroscopy, and ultrasound to see if it can identify tumor tissue and blood vessels in adults with high-grade glioma.
-
Fluorescent-labeled nivolumab (Nivo800) imaging for high-grade glioma surgery
This trial tests whether a near-infrared fluorescent version of the immunotherapy drug nivolumab can be given before planned surgery to visualize drug distribution in adults with suspected high-grade glioma.
-
First-line bevacizumab versus dexamethasone for symptomatic cerebral radiation necrosis after radiation for high-grade glioma or brain metastases.
This trial will test whether first-line bevacizumab or dexamethasone works better at reducing symptoms in adults with symptomatic cerebral radiation necrosis after radiation for high-grade glioma or brain metastases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.